Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy

Journal of Emergency Medicine

Volumn 27, Issue 4, 2004, Pages 395-405

  Katz, Eric ^a,e   Larsen, L Scott ^b   Fogarty, Charles M ^c   Hamed, Kamal ^d   Song, James ^d   Choudhri, Shurjeel ^d  

^a WASHINGTON UNIVERSITY   (United States)

^b Bayshore Community Hospital   (United States)

^c Lung and Chest Medical Associates   (United States)

^d BAYER CORPORATION   (United States)

^e St Louis MO 63110 ^*  (United States)

Author keywords

azithromycin; ceftriaxone; cefuroxime; community acquired pneumonia; moxifloxacin

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RASH; RELIABILITY; SIDE EFFECT; URTICARIA; VISUAL DISORDER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; AZITHROMYCIN; CEFTRIAXONE; COMMUNITY-ACQUIRED INFECTIONS; CONSTIPATION; DRUG THERAPY, COMBINATION; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; NAUSEA; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; QUINOLINES; SAFETY; TIME FACTORS; TREATMENT OUTCOME;

EID: 6344243659     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2004.02.023     Document Type: Article

References (35)

1. J.G. Bartlett, L.M. Mundy Community-acquired pneumonia N Engl J Med 333 1995 1618 1624
2. M. Woodhead Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Eur Respir J Suppl 36 2002 20s-7s
3. V. Monge, V.M. San-Martin, A. Gonzalez The burden of community-acquired pneumonia in Spain Eur J Public Health 11 2001 362 364
4. V. Kaplan, D.C. Angus, M.F. Griffin, G. Clermont, R. Scott Watson, W.T. Linde-Zwirble Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States Am J Respir Crit Care Med 165 2002 766 772
5. J.G. Barlett, S.F. Dowell, L.A. Mandell, T.M. File Jr, D.M. Musher, M.J. Fine Practice guidelines for the management of community-acquired pneumonia in adults Clin Infect Dis 31 2000 347 382
6. Marston B, Plouffe J, Breiman R. Preliminary findings in a community-based pneumonia incidence study. Am Soc Microbiol 1993:36-7.
7. M.J. Fine, T.E. Auble, D.M Yealy A prediction rule to identify low-risk patients with community-acquired pneumonia N Engl J Med 336 1997 243 250
8. P.C. Appelbaum Resistance among Streptococcus pneumoniae: implications for drug selection Clin Infect Dis 34 2002 1613 1620
9. J.P. Metlay Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes Curr Opin Infect Dis 15 2002 163 167
10. T.M. File Jr Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae Clin Infect Dis 34 Suppl 1 2002 S17 26
11. McCormick AW, Whitney CG, Farley MM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med, Advance online publication, http://www.nature.com/ naturemedicine.
12. F. Marco, E. Bouza, J. Garcia-de-Lomas, and L. Aguilar Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: the impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics. The Spanish Surveillance Group for Respiratory Pathogens J Antimicrob Chemother 46 2000 557 564
13. A.B. Brueggemann, K.C. Kugler, G.V. Doern In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Antimicrob Agents Chemother 41 1997 1594 1597
14. M.E. Jones, A.M. Staples, I. Critchley Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States Antimicrob Agents Chemother 44 2000 2645 2652
15. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999 MMWR Morb Mortal Wkly Rep 50 2001 800 804
16. R. Davidson, R. Cavalcanti, J.L Brunton Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia N Engl J Med 346; 2002 747 750
17. P.E. Empey, H.R. Jennings, A.C. Thornton, R.P. Rapp, M.E. Evans Levofloxacin failure in a patient with pneumococcal pneumonia Ann Pharmacother 35 2001 687 690
18. M.B. Kays, D.W. Smith, M.F. Wack, G.A. Denys Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia Pharmacotherapy 22 2002 395 399
19. Ferraro MJ, Brown S, Harding I. Prevalence of fluoroquinolone resistance amongst Streptococcus pneumoniae isolated in the United States during the winter of 2000-01. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002.
20. W.M. Scheld Maintaining fluoroquinolone class efficacy: review of influencing factors Emerg Infect Dis 9 2003 1 9
21. M.S. Niederman, L.A. Mandell, A. Anzueto Guidelines for the management of adults with community-acquired pneumonia Diagnosis, assessment of severity, antimicrobial therapy, and prevention Am J Respir Crit Care Med 163 2001 1730 1754
22. F. Vogel Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents? Drugs 62 2002 309 317
23. E.A. Halm, M.J. Fine, T.J. Marrie Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines JAMA 279 1998 1452 1457
24. K.E. Aldridge, D.S. Ashcraft Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes Antimicrob Agents Chemother 41 1997 709 711
25. A.P. MacGowan, K.E. Bowker, H.A. Holt, M. Wootton, D.S. Reeves Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria J Antimicrob Chemother 40 1997 503 509
26. F.J. Boswell, J.M. Andrews, G. Jevons, R. Wise Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance J Antimicrob Chemother 50 2002 495 502
27. T.A. Davies, R. Goldschmidt, S Pfleger Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000) J Antimicrob Chemother 52 2003 168 175
28. G.W. Waterer, G.W. Somes, R.G. Wunderink Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia Arch Intern Med 161 2001 1837 1842
29. R. Finch, D. Schurmann, O. Collins Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment Antimicrob Agents Chemother 46 2002 1746 1754
30. T.M. File, L.S. Larsen, C.M. Fogarty Safety and Efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients Todays Ther Trends 19 2001 251 270
31. M.F. Drummond, D.L. Becker, M. Hux An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia Chest 124 2003 526 535
32. A. Torres, J.F. Muir, P. Corris Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Eur Respir J 21 2003 135 143
33. H. Lode, A. Lubasch, M. Raffenberg, H. Mauch Clinical results in the treatment of respiratory infections with moxifloxacin Drugs Today (Barc) 36 2000 245 253
34. G. Hoeffken, H.P. Meyer, J. Winter, L. Verhoef CAP1 Study Group The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia Respir Med 95 2001 553 564
35. P. Petitpretz, P. Arvis, M. Marel, J. Moita, J. Urueta Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults Chest 119 2001 185 195